<DOC>
	<DOCNO>NCT01554189</DOCNO>
	<brief_summary>This study do assess safety , pharmacokinetics ( PK ) pharmacodynamics ( PD ) MK-8325 male hepatitis C virus ( HCV ) -infected participant . There 3 part study . Part I enroll genotype 1 ( GT1 ) HCV patient , Part II enroll genotype 3 ( GT3 ) HCV-infected participant , Part III enroll GT1a HCV-infected participant . All part may run concurrently , may stagger needed clinical site .</brief_summary>
	<brief_title>A Study Evaluate Safety , Pharmacokinetics Pharmacodynamics MK-8325 Hepatitis C-Infected Males ( MK-8325-002 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<criteria>Inclusion criterion : Body mass index ( BMI ) 18 ≤37 kg/m^2 Diagnosis chronic HCV infection Must infect HCV GT1a , GT1b , GT3 Exclusion criterion : Coinfection GT1 GT3 HCV History stroke , chronic seizure , major neurological disorder History clinically significant endocrine , gastrointestinal ( except HCV infection ) , cardiovascular , hematological , immunological , renal , respiratory , genitourinary abnormality diseases History neoplastic disease Positive Hepatitis B surface antigen History human immunodeficiency virus ( HIV ) infection positive HIV serology Major surgery , donate lose 1 unit blood ( approximately 500 mL ) participate another investigational study within 4 week prior History significant multiple and/or severe allergy ( include latex allergy ) , anaphylactic reaction significant intolerability prescription nonprescription drug food Current regular user ( include `` recreational use '' ) illicit drug history drug ( include alcohol ) abuse within approximately 2 month Evidence history chronic hepatitis cause HCV include limited nonHCV viral hepatitis , nonalcoholic steatohepatitis ( NASH ) , druginduced hepatitis , autoimmune hepatitis Previous treatment ( ) nonstructural 5A ( NS5A ) protein inhibitor Treatment protease inhibitor ( ) &lt; 30 day prior study enrollment Previous exposure interferonalpha and/or ribavirin within 3 month prior first dose MK8325 study Clinical laboratory evidence advance decompensated liver disease ; evidence bridge fibrosis high grade fibrosis ( Metavir score ≥3 ) prior liver biopsy</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>